Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes
Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes
复制标题
DOI：
10.1080/10428190802541815
复制
发表时间：
2008-01-01
影响因子：
2.6
通讯作者：
Naoe, Tomoki
中科院分区：
文献类型：
--
作者：
Ishikawa, Yuichi;Xu, Jinglan;Naoe, Tomoki
位于5q35染色体上的核磷蛋白1 （NPM1）基因在骨髓增生异常综合征（MDS）和急性髓性白血病（AML）中受到染色体易位、突变和缺失的影响。据报道，NPM1单倍不全在敲除小鼠中引起mds样疾病。在这里，我们研究了36例MDS患者骨髓（BM）样本中mRNA和蛋白的表达。NPM1 mRNA和蛋白的表达水平与5号染色体异常无关，与正常BM和AML细胞基本相同。然而，NPM1突变的AML细胞中的蛋白质水平略低于未突变的细胞。免疫化学研究显示MDS和正常骨髓细胞在染色强度和亚细胞定位上没有差异。结论：异常的细胞质定位和/或NPM1蛋白水平的显著降低在MDS中很少发生。核npm1阳性细胞数量的增加可能与MDS的进展有关。
The Nucleophosmin1 (NPM1) gene located in chromosome 5q35 is affected by chromosomal translocation, mutation and deletion in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). NPM1 haploinsufficiency reportedly causes MDS-like disorders in knockout mice. Here, we studied mRNA and protein expression in bone marrow (BM) samples from 36 patients with MDS. The NPM1 expression levels of mRNA and protein were not related to chromosome 5 abnormalities and were almost the same as those in normal BM and AML cells. However, the protein levels in AML cells with NPM1 mutations were slightly lower than in those without mutation. Immunochemical studies showed no difference in the staining intensity and subcellular localisation between MDS and normal BM cells. It was concluded that abnormal cytoplasmic localisation and/or significant reduction of NPM1 protein level rarely occurs in MDS. The increase in the number of nuclear NPM1-positive cells may be related to the progression of MDS.